Skip to content
Some menu
Korean
Contact
Recruit
Main menu
R&D
Business
Products
CSR
Investor
Company
Full menu
R&D
Introduction
Technology
LAPSCOVERY
PENTAMBODY
BIO Discovery
NCE Discovery
IMD•New Formulation
Pipeline
by Therapeutic Area
by Research Area
Achievement
Business
Open Innovation
Licensing-out
Licensing-in
Global Presence
Facilities
Paltan Plant
Fine Chemical
Cepha Plant
Bio Plant
Products
Product search
CSR
Ethical Management
Environmental Management
Social Contribution
Talent Management
Governance
CSR Report
Investors
Stock Information
Stock Quote & Chart
Market View
Finance
Summarized Balance Sheet
Summarized Income Statement
Credit Ratings
IR Center
IR Event
Analyst Coverage
Management
Company
CEO’s Greeting
About Hanmi
Overview
History
Location
News
Compliance Program
Summary of the CP
Compliance Manual
Affiliates
Open full menu
Search
Full menu
R&D
Introduction
Technology
Pipeline
Achievement
Business
Licensing-out
Licensing-in
Global Presence
Facilities
Products
Product search
CSR
Ethical Management
Environmental Management
Social Contribution
Talent Management
Governance
CSR Report
Investors
Stock Information
Finance
IR Center
Management
Company
CEO’s Greeting
About Hanmi
News
Compliance Program
Affiliates
Products Search
Product Search
Search
Close
카테고리메뉴
Home
R&D
Business
Products
CSR
Investor
Company
R&D
Introduction
Technology
LAPSCOVERYt
PENTAMBODY
BIO Discovery
NCE Discovery
IMD•New Formulation
Pipeline
by Therapeutic Area
by Research Area
Achievement
Business
Open Innovation
Licensing-out
Platform Technology & NCEs
Fixed Dose Combinations(FDC)
Value Added Generics(VAG)
Licensing-in
Global Presence
Facilities
Paltan Plant
Fine Chemical
Cepha Plant
Bio Plant
Products
Product search
Investors
Stock Information
Real Time
Market View
Financial Information
Summarized Balance Sheet
Summarized Income Statement
Credit Ratings
IR Center
IR Event
Analyst Coverage
Management
Company
Greeting
About Hanmi
Overview
History
2015
2014
2013
2012
2011
2010
2009~2000
1999~1973
Location
Hanmi Pharm.
R&D Center
Paltan Plant
Pyeongtaek Plant
News
Affiliates
Intro
Intro
Ethical Management
Summary of the CP
What is the CP?
Operation of Organization
History
Compliance Manual
Environmental Management
EHS Policy
Environmental sustainability
Certifications and Awards
Social Contribution
The Joy of Sharing
Support for Public Healthcare
Pharmaceutical Aid
Hanmi Cham Medical Professional Award
Hanmi Proud Doctor Award
Hanmi Small and Mid-Sized Hospital Award
Hanmi Essay Literature Award
Hanmi Young Medicine Scholarship
HMP Photography Contest
Global CSR
Mecenat
Community Involvement and Development
Talent Management
Employee Competency Improvement
Employee Welfare Benefits
Employee Health and Safety
Employment Index
Certifications and Awards
Governance
Shareholder
Board of Directors
Committee
Audit Committee
CSR Committee
hEHS Committee
CSR Report
Company
About Hanmi
한미약품은 창조와 도전을 기치로 신약개발에 매진하는
R&D중심 제약기업
입니다.
Overview
History
Location
History
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009~2000
1999~1973
Nov
Hanmi new RFID reader, grand prize for national excellence patent award
Phase 1 clinical trial of HM95573,a next-generation targeted therapy for melanoma treatment
Oct
Beijing Hanmi, received 'Presidential Prize' at 2014 Korea well-respected corporate awards
Received 'Minister Prize of Health and Welfare' at Sharing Korea awards
Sep
Diabetes-obesity biologics, presented at EASD
Aug
License agreement with Luye pharma group for targeted anti-cancer dug 'Poziotinib' in China
Diabetes biologic, '
LAPS
efpeglenatide', completed patient recruitment in phase IIb clinical trial
Jul
Contract with Actavis for exporting a hyaluronic acid injection
Hanmi opened the official blog 'Saranghanmida'
Hanmi-Novartis, diabetes treatment 'Galvus' co-promotion
Jun
Triaxone, obtained market authorization in 4 EU countries
sup>LAPSInsulin, weekly diabetes drug, presented at ADA
Rheumatoid arthritis drug, HM71224, presented at EULAR
The 8th Hanmi mid-small hospital award, Seungwon Hong, Director of Daejeon Christian General Hosipital
Plant in Pyeongtaek awarded for joining PIC/S by Korea Food & Drug Administration
May
Diabetes-obesity new drug (
LAPS
-GLP-1/GCG) enters into global phase 1
Apr
Probiotics for kids in Beijing Hanmi, 'Mamiai' is registered as China Famous Trade Mark
Decided to build an extension of BioPlant in Pyeongtaek
Received 'fair trade corporation' award by Fair Trade Commission
Launched Fluterol, DPI type asthma treatment drug
Mar
4th shareholders meeting of Hanmi Pharmaceuticals / 41st shareholders meeting of Hanmi Science
License agreement with Access Pharmaceuticals for Korean commercialization of 'Mugard'
Feb
Hanmi-MSD, mutual co-promotion agreement for the sales of 12 products
Succeeded in seasoned equity offering (1 million shares)
Jan
Hit 100 billion won in research and development as the first listed pharmaceutical company
Only one in the pharmaceutical industry to receive CP certificate(BBB grade)